The Role of Psychotherapy in the Care of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Grande, Tilman, Grande, Bettina, Gerner, Patrick et al. · Medicina (Kaunas, Lithuania) · 2023 · DOI
Quick Summary
This article discusses how talking therapy (psychotherapy) might help people with ME/CFS cope better, even though it cannot cure the disease itself. The authors emphasize that ME/CFS is a physical illness requiring physical treatments, and they highlight that post-exertional malaise (getting worse after activity) is a key symptom that therapists should understand. They propose a practical approach to therapy that respects these facts while still helping patients manage their emotional wellbeing.
Why It Matters
This editorial addresses a critical gap in ME/CFS care: recognizing that while the disease is biological, patients' psychological wellbeing and coping capacity deserve therapeutic support. It validates concerns many patients have about psychosomatic framing while still advocating for mental health care that respects the biological reality of the condition. This framework helps guide how therapists should approach ME/CFS patients ethically and effectively.
Observed Findings
Psychotherapy and psychosomatic rehabilitation have not demonstrated curative effects in ME/CFS treatment according to current research.
Many ME/CFS patients experience severe mental suffering despite the physical nature of their illness.
Post-exertional malaise (symptom worsening after activity) is a cardinal feature requiring specific therapeutic attention.
Patients' mental well-being and coping strategies can benefit from appropriately framed psychotherapeutic support.
ME/CFS is recognized as a post-infectious, physical disease with a long medical history (coded since 1969).
Inferred Conclusions
Psychotherapy should not be positioned as a cure for ME/CFS but rather as supportive care for psychological wellbeing within a biomedical framework.
Therapists working with ME/CFS patients must understand and respect post-exertional malaise as a physical symptom limiting activity capacity.
Current psychosomatic disease models of ME/CFS lack empirical support and should not be used as primary treatment rationales.
A revised psychotherapeutic approach can serve ME/CFS patients' emotional and coping needs while acknowledging the disease's fundamentally biological nature.
Remaining Questions
What This Study Does Not Prove
This editorial does not provide new empirical data or clinical trial results proving specific psychotherapeutic interventions are effective for ME/CFS. It cannot establish which types of therapy are most beneficial or what outcomes patients might achieve. As an opinion piece, it reflects current consensus but does not constitute independent experimental evidence.
Which specific psychotherapeutic techniques are most effective at supporting mental health in ME/CFS without reinforcing harmful misconceptions about causation?
How should therapists be trained to safely support ME/CFS patients while avoiding activity-based interventions that could worsen physical symptoms?
What are the optimal indicators for when psychotherapy would be most beneficial for an individual ME/CFS patient?
How can mental health support be effectively integrated into multidisciplinary biomedical treatment approaches for ME/CFS?